$17.5 B

BMRN Mkt cap, 22-Jun-2018

$373.4 M

BioMarin Pharmaceutical Revenue Q1, 2018
BioMarin Pharmaceutical Gross profit (Q1, 2018)291.1 M
BioMarin Pharmaceutical Gross profit margin (Q1, 2018), %78%
BioMarin Pharmaceutical Net income (Q1, 2018)-44.1 M
BioMarin Pharmaceutical EBIT (Q1, 2018)-44.4 M
BioMarin Pharmaceutical Cash, 31-Mar-2018474 M

BioMarin Pharmaceutical Revenue Breakdown

Embed Graph

BioMarin Pharmaceutical revenue breakdown by geographic segment: 18.4% from Rest of the World , 13.3% from Latin America, 22.7% from Europe and 45.5% from United States

BioMarin Pharmaceutical Financials

BioMarin Pharmaceutical Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

548.5 m751 m889.9 m1.1 b

Revenue growth, %

37%18%26%

Cost of goods sold

95.7 m129.8 m152 m209.6 m

Gross profit

452.7 m621.3 m737.9 m907.2 m

Gross profit Margin, %

83%83%83%81%

R&D expense

661.9 b

General and administrative expense

476.6 b

Operating expense total

1.1 t

EBIT

(156 m)(92.9 m)(110.7 m)(803.4 m)

EBIT margin, %

(28%)(12%)(12%)(72%)

Interest expense

10.4 m36.6 m38.2 m39.5 m

Interest income

3.1 m5.9 m4.5 m7.5 b

Pre tax profit

(176.5 m)(124.9 m)(154.7 m)(831.1 m)

Income tax expense

(150 k)9.1 m17.1 m(200.8 m)

Net Income

(176.4 m)(134 m)(171.8 m)(630.2 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

136.9 m151.6 m191.8 m176.8 m203.3 m250.5 m208.9 m236.7 m300 b279.9 m303.7 m317.4 m334.1 m373.4 m

Cost of goods sold

28.1 m22.8 m31.2 m29.9 m32.8 m39.9 m36.7 m43.1 m51.6 b50.7 m50 m56.3 m59.5 m82.3 m

Gross profit

108.8 m128.7 m160.6 m146.9 m170.5 m210.6 m172.2 m193.6 m248.4 b229.2 m253.7 m261.1 m274.7 m291.1 m

Gross profit Margin, %

80%85%84%83%84%84%82%82%83%82%84%82%82%78%

R&D expense

88.1 m86.2 m107.7 m125.7 m142.1 m157.9 m158.7 m158.8 m167 b160.8 m145 m143 m154.1 m183.9 m

General and administrative expense

61.8 m60.1 m68.1 m74.6 m92.8 m101.5 m94 m105.3 m110 b118.8 m120 m143.5 m130.5 m138.3 m

Operating expense total

187.6 m178 m210.7 m165.6 m269.1 m314.8 m290.8 m317.7 m873 b340 m324 m356.3 m347.9 m417.8 m

EBIT

(50.7 m)(26.5 m)(18.9 m)11.2 m(65.9 m)(64.2 m)(81.9 m)(80.9 m)(573 b)(60.1 m)(20.2 m)(38.8 m)(13.7 m)(44.4 m)

EBIT margin, %

(37%)(17%)(10%)6%(32%)(26%)(39%)(34%)(191%)(21%)(7%)(12%)(4%)(12%)

Interest expense

526 k9.1 m9.2 m9.1 m9.5 m10 m9.4 m9.8 m9.9 b10 m10.1 m10 m10.9 m11.6 m

Interest income

574 k1.1 m1.7 m1.4 m683 k1 m1.3 m1.6 m1.4 b1.6 m3.1 m3 m4 m5.2 m

Pre tax profit

(52.3 m)(34.6 m)(27.7 m)3.2 m(74.7 m)(82.5 m)(90.4 m)(89.1 m)(583 b)(66.8 m)(24.3 m)(45.5 m)(20.6 m)(50.8 m)

Income tax expense

704 k3.5 m5.8 m(4.2 m)(7.2 m)(555 k)483 k(24 m)(6.7 m)

Net Income

(53 m)(38.1 m)(33.5 m)7.4 m(67.5 m)(82 m)(90.9 m)(85.1 m)(424 b)(42.8 m)(16.3 m)(36.8 m)(12.5 m)(44.1 m)

BioMarin Pharmaceutical Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

568.8 m875.5 m397 m408.3 m

Accounts Receivable

117.8 m144.5 m165 m215.3 m

Inventories

162.6 m199.5 m271.7 m355.1 m

Current Assets

1.1 b1.4 b1.1 b1.4 b

PP&E

319.3 m523.5 m704.2 m798.8 m

Goodwill

54.3 m54.3 m197 m197 m

Total Assets

2.2 b2.5 b3.7 b4 b

Accounts Payable

370.5 m

Current Liabilities

183.3 m235.7 m445.5 m439.3 m

Total Liabilities

1.3 b

Additional Paid-in Capital

2.1 b2.4 b3.4 b4.3 b

Retained Earnings

(715.8 m)(849.8 m)(1 b)(1.5 b)

Total Equity

1.3 b1.5 b2.4 b2.8 b

Financial Leverage

1.7 x1.6 x1.6 x1.5 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

181.6 m639.8 m584.7 m398 m900.6 m440.7 m376.3 m270.5 m306 m707.3 m348.2 m354.9 m431.4 m474 m

Accounts Receivable

124.7 m110.5 m122.3 m121.4 m175.7 m186.1 m148.9 m180.8 m214.2 m215.9 m230.3 m238.3 m251.9 m318.4 m

Inventories

148.7 m176.9 m193.5 m204.4 m222.8 m237.5 m262.1 m297 m326.6 m347.4 m384.1 m429.8 m457.4 m468.2 m

Current Assets

713.5 m1.2 b1.2 b1.1 b1.5 b1.2 b1.2 b992.8 m1.1 b1.7 b1.4 b1.5 b2.1 b2.2 b

PP&E

285.7 m437.1 m469.9 m486.7 m538.1 m568.1 m604.5 m716.9 m724.5 m729.8 m824 m851.1 m878.6 m895.4 m

Goodwill

54.3 m54.3 m54.3 m54.3 m202.4 m202.4 m202.4 m197 m197 m197 m197 m197 m197 m197 m

Total Assets

1.6 b2.3 b2.3 b2.4 b3.7 b3.6 b3.6 b3.7 b3.1 b3.8 b3.9 b4 b4.6 b4.6 b

Accounts Payable

167.6 m156 m166.7 m206.6 m230.2 m256.3 m296.2 m290.6 m292.3 m306.1 m272.4 m319.2 m364.9 m346.5 m

Current Liabilities

167.6 m156 m166.7 m206.6 m305.5 m347.7 m390.5 m388 m364.6 m377.3 m340.2 m374.3 m417.5 m773.5 m

Total Liabilities

344 m880.6 m883.7 m932 m1.2 b1.3 b1.3 b1.4 b1.2 b1.2 b1.2 b1.2 b1.8 b1.8 b

Additional Paid-in Capital

1.9 b2.2 b2.2 b2.3 b3.3 b3.3 b3.4 b3.4 b3.5 b4.2 b4.3 b4.4 b4.4 b4.5 b

Retained Earnings

(653.8 m)(753.9 m)(787.4 m)(780 m)(917.3 m)(999.3 m)(1.1 b)(1.1 b)(1.5 b)(1.6 b)(1.5 b)(1.6 b)(1.6 b)(1.7 b)

Total Equity

1.3 b1.5 b1.5 b1.5 b2.4 b2.3 b2.3 b1.9 b2.6 b2.8 b2.8 b2.8 b2.8 b

Financial Leverage

1.3 x1.6 x1.6 x1.6 x1.5 x1.6 x1.6 x1.6 x1.5 x1.4 x1.4 x1.6 x1.6 x

BioMarin Pharmaceutical Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(176.4 m)(134 m)(171.8 m)(630.2 m)

Depreciation and Amortization

47.3 m56.7 m47.2 m96.9 m

Accounts Receivable

(8.8 m)(27 m)(16 m)(51.5 m)

Inventories

(34 m)(37 m)(51 m)(64.5 m)

Cash From Operating Activities

(59.6 m)(73.5 m)(221.7 m)(227.8 m)

Purchases of PP&E

(65.1 m)(118.8 m)(227.7 m)(148.4 m)

Cash From Investing Activities

(298.8 m)194.6 m(1.2 b)(484 m)

Cash From Financing Activities

746.7 m185.7 m927.9 m727.1 m

Income Taxes Paid

14.9 m35 m16.1 m95.9 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(53 m)(38.1 m)(33.5 m)7.4 m(67.5 m)(82 m)(90.9 m)(85.1 m)(424 b)(42.8 m)(16.3 m)(44.1 m)

Depreciation and Amortization

23.6 m

Accounts Receivable

122.3 m121.4 m175.7 m186.1 m148.9 m180.8 m214.2 m215.9 m230.3 m(26.3 m)

Inventories

193.5 m204.4 m222.8 m237.5 m262.1 m297 m326.6 m347.4 m384.1 m10.8 m

Accounts Payable

(51.9 m)

Cash From Operating Activities

(42.5 m)

Purchases of PP&E

(30.2 m)

Cash From Investing Activities

(71.7 m)

Cash From Financing Activities

(9.8 m)

Interest Paid

1.5 m

Income Taxes Paid

11.7 m

BioMarin Pharmaceutical Ratios

USDY, 2018

Financial Leverage

1.6 x
Report incorrect company information

BioMarin Pharmaceutical Operating Metrics

BioMarin Pharmaceutical's Patent Applications was reported to be 426 in FY, 2016.
FY, 2016

Patent Applications

426

Patents Issued

1.17 k

Phase 1/2 Trials Products

2

Phase III Trials Products

2
Report incorrect company information